Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTFields with gemcitabine and nab-paclitaxel in locally-advanced pancreatic adenocarcinoma
NCT03377491Phase 3Completed
- Sponsor
- NovoCure
- Start
- May 2018
- Primary completion
- Oct 2024
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by NovoCure. Primary endpoint: Overall Survival. Started May 2018; status: completed.
Beyond the preview
Go deeper on NCT03377491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03377491.